These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 33087494

  • 21. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
    Luigetti M, Di Paolantonio A, Guglielmino V, Romano A, Rossi S, Sabino A, Servidei S, Sabatelli M, Primiano G.
    Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
    Romano A, Primiano G, Antonini G, Ceccanti M, Fenu S, Forcina F, Gentile L, Inghilleri M, Leonardi L, Manganelli F, Obici L, Sabino A, Sciarrone MA, Tozza S, Vitali F, Luigetti M.
    Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M, HELIOS-A Collaborators.
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [Abstract] [Full Text] [Related]

  • 27. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
    Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, Gollob J, Coelho T.
    BMC Neurol; 2017 Sep 11; 17(1):181. PubMed ID: 28893208
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA, Mauermann ML, Grogan M, Coelho T.
    Brain Behav; 2019 Sep 11; 9(9):e01371. PubMed ID: 31368669
    [Abstract] [Full Text] [Related]

  • 31. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL, Claeys KG, Delstanche S, Van Parys V, Baets J, Tilleux S, Remiche G.
    Acta Neurol Belg; 2023 Jun 11; 123(3):1029-1037. PubMed ID: 36829087
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.
    Milani P, Mussinelli R, Perlini S, Palladini G, Obici L.
    Expert Opin Pharmacother; 2019 Dec 11; 20(18):2223-2228. PubMed ID: 31566422
    [Abstract] [Full Text] [Related]

  • 34. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I.
    Clin Auton Res; 2019 Sep 11; 29(Suppl 1):11-17. PubMed ID: 31399774
    [Abstract] [Full Text] [Related]

  • 35. [ATTRv amyloidosis with early improvement demonstrated by the 6-minute walk test following Patisiran therapy: a case report].
    Oginezawa S, Ishihara T, Iwafuchi Y, Hatano Y, Kashimura K, Onodera O.
    Rinsho Shinkeigaku; 2022 May 31; 62(5):375-379. PubMed ID: 35474286
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E, Aranda-Vela K, Cervantes-Hernández A, López-Cureño S.
    Am J Kidney Dis; 2024 Aug 31; 84(2):224-231. PubMed ID: 38484868
    [Abstract] [Full Text] [Related]

  • 38. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.
    Pernice HF, Knorz AL, Wetzel PJ, Herrmann C, Muratovic H, Rieber F, Asaad E, Fiß G, Barzen G, Blüthner E, Knebel F, Spethmann S, Messroghli D, Heidecker B, Brand A, Wetz C, Tschöpe C, Hahn K.
    Sci Rep; 2024 May 02; 14(1):10111. PubMed ID: 38698025
    [Abstract] [Full Text] [Related]

  • 39. Hereditary transthyretin amyloidosis: current treatment.
    Adams D, Slama M.
    Curr Opin Neurol; 2020 Oct 02; 33(5):553-561. PubMed ID: 32796279
    [Abstract] [Full Text] [Related]

  • 40. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.
    Neurodegener Dis Manag; 2019 Feb 02; 9(1):5-23. PubMed ID: 30480471
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.